Cinobufotalin Ameliorates the Development of Pulmonary Fibrosis by Suppressing the TGF ‐β/Smad Pathway via Regulating PI15
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70788 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Dong Xia und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China. Hauptthemen laut MEDLINE: Bufanolides, Pulmonary Fibrosis, Signal Transduction, Smad Proteins. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Science and Technology Program of Guangzhou, the Discipline construction project of Guangdong Medical University, the National Natural Science Foundation of China.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a common hallmark of several types of interstitial lung diseases (ILDs), for which effective therapeutic drugs are lacking. The small‐molecule chemical compound cinobufotalin (CB) has demonstrated significant anti‐cancer effects in lung cancer. In this study, we first found that CB attenuated bleomycin (BLM)‐induced PF and inhibited transforming growth factor‐beta 1 (TGF‐β1)‐induced myofibroblast activation and epithelial‐mesenchymal transition (EMT). Subsequently, comparative RNA sequencing (RNA‐Seq) was conducted to analyse the lung gene expression profiles in mice. Interestingly, peptidase inhibitor 15 (PI15) was identified as a significantly differentially expressed gene (DEG) and may be a potential target in PF progression. Mechanistic studies showed that CB exerts anti‐PF effects by inhibiting PI15 and thereby regulating the TGF‐β/Smad signalling pathway. Our data demonstrated that CB represents a promising anti‐PF drug and may be a candidate therapeutic for PF patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Dongguan Songshan Lake Central Hospital, Guangdong Medical University, Dongguan, China.
- Department of Respiratory Medicine, The Second Affiliated Hospital of Hainan Medical University, Haikou, China.
- Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
ORCID-Profile: Dong Xia
Förderung
- the Science and Technology Program of Guangzhou
- the Discipline construction project of Guangdong Medical University
- the National Natural Science Foundation of China
- the Open Foundation of NHC Key Laboratory of Tropical Disease Control, Hainan Medical University
- National Natural Science Foundation of China
Zitieren
APA
Xia, D., Liu, X., Yang, Q., Li, J., Li, L., You, Y., Wang, J., Fang, W., & Yang, H. (2025). Cinobufotalin Ameliorates the Development of Pulmonary Fibrosis by Suppressing the TGF ‐β/Smad Pathway via Regulating PI15. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70788
Vancouver
Xia D, Liu X, Yang Q, Li J, Li L, You Y, et al. Cinobufotalin Ameliorates the Development of Pulmonary Fibrosis by Suppressing the TGF ‐β/Smad Pathway via Regulating PI15. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70788
BibTeX
@article{Xia2025,
author = {Xia, Dong and Liu, Xingyan and Yang, Qiuting and Li, Jie and Li, Li and You, Yong and Wang, Jing and Fang, Weiyi and Yang, Huiling},
title = {Cinobufotalin Ameliorates the Development of Pulmonary Fibrosis by Suppressing the TGF ‐β/Smad Pathway via Regulating PI15},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70788}
}
EUVIMED